# HOUSE HEALTH AND HUMAN SERVICES COMMITTEE SUBSTITUTE FOR HOUSE BILL 112

## 53RD LEGISLATURE - STATE OF NEW MEXICO - FIRST SESSION, 2017

4

1

2

3

5

6

7

8 9

10

11

12 13

14

15

16

17

18

19

20 21

22

23

24

25

AN ACT

RELATING TO HEALTH COVERAGE; AMENDING SECTIONS OF THE HEALTH CARE PURCHASING ACT, THE NEW MEXICO INSURANCE CODE, THE HEALTH MAINTENANCE ORGANIZATION LAW AND THE NONPROFIT HEALTH CARE PLAN LAW TO MAKE CHANGES TO PRESCRIPTION DRUG BENEFITS ADMINISTRATION REQUIREMENTS.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF NEW MEXICO:

**SECTION 1.** Section 13-7-15 NMSA 1978 (being Laws 2013, Chapter 138, Section 1) is amended to read:

"13-7-15. PRESCRIPTION DRUGS--PROHIBITED FORMULARY CHANGES -- NOTICE REQUIREMENTS . --

A. [As of January 1, 2014] Group health coverage, including any form of self-insurance, offered, issued or renewed under the Health Care Purchasing Act that provides coverage for prescription drugs categorized or tiered for .206394.2

purposes of cost-sharing through deductibles or coinsurance
obligations shall [not] only make any of the following changes
to coverage for a prescription drug [within one hundred twenty
days of any previous change to coverage for that prescription
drug, unless a generic version of the prescription drug is
available at the time of group health plan renewal:

- (1) reclassify a drug to a higher tier of the formulary;
- (2) reclassify a drug from a preferred classification to a non-preferred classification, unless that reclassification results in the drug moving to a lower tier of the formulary;
- (3) increase the cost-sharing, copayment, deductible or coinsurance charges for a drug;
  - (4) remove a drug from the formulary;
- (5) establish a prior authorization requirement;
- (6) impose or modify a drug's quantity limit;
  or
  - (7) impose a step-therapy restriction.
- B. Nothing in this section shall be construed to prohibit a group health plan administrator from adding a new drug, generic or otherwise, to a group health plan formulary during a plan year.
- [B.] C. The administrator for the group health .206394.2

1	coverage shall [give the affected enrollee at least sixty days'
2	advance written notice of the impending change when it is
3	determined that one of the following modifications will made to
4	a formulary:
5	(1) reclassification of a drug to a higher
6	tier of the formulary;
7	(2) reclassification of a drug from a
8	preferred classification to a non-preferred classification,
9	unless that reclassification results in the drug moving to a
10	lower tier of the formulary;
11	(3) an increase in the cost-sharing,
12	copayment, deductible or coinsurance charges for a drug;
13	(4) removal of a drug from the formulary;
14	(5) addition of a prior authorization
15	requirement;
16	(6) imposition or modification of a drug's
17	quantity limit; or
18	(7) imposition of a step-therapy restriction
19	for a drug] make available to enrollees the formulary for a
20	given plan year no later than sixty days prior to the
21	enrollment deadline for the plan year.
22	D. A group health plan administrator shall
23	establish the following provisions relating to any new drug at
24	the time that the drug is added to a group health plan
25	formulary and shall not modify any of the following provisions
	.206394.2

1	<u>until</u>
2	
3	
4	prefe
5	
6	<u>requi</u>
7	
8	
9	
10	
11	gener
12	<u>than</u>
13	<u>plan</u>
14	<u>deduc</u>
15	<u>exist</u>
16	<u>thera</u>
17	<u>for t</u>
18	<u>dosag</u>
19	<u>admin</u>
20	effec
21	any c
22	coins
23	<u>equiv</u>
24	plan

_	_	_	_	_	_		_	
11ntil	the	renewal	date	for	the	following	nlan	vear:
uiicxx	CIIC	LCIICWAL	uucc	TOT	CIIC	TOTTOWILE	PIGII	, car •

- (1) drug tier classification;
- (2) classification as preferred or non-

rred;

- (3) copayment, deductible or coinsurance rements for a drug;
  - (4) prior authorization requirements;
  - (5) drug quantity limit; or
  - (6) any step-therapy restriction.

E. When a group health plan administrator adds a ic drug to a group health plan formulary at any time other at the time of group health plan renewal, the group health administrator may adjust the cost-sharing, copayment, tible or coinsurance requirements, in accordance with the ing schedule of benefits, applicable to the drug's peutic equivalent that was already in the drug formulary hat plan year; provided that the drug is equivalent in e form, safety, strength, chemical composition, route of istration, quality, performance characteristics and side ts. The group health plan administrator shall not make hange to the cost-sharing, copayment, deductible or urance requirements applicable to the generic drug's alent more than once during any plan year. A group health plan administrator shall give enrollees at least sixty days' advance written notice before making any changes to

2	<u> </u>
3	
4	S
5	8
6	1
7	
8	C
9	
10	1
11	
12	1
13	•
14	1
15	
16	C
17	
18	-
19	
20	1
21	-
22	
23	1
24	
25	

cost-sharir	ıg,	copa	yment,	deductil	ole c	r coi	nsurance	e req	uirement	S
		_	•							
applicable	to	the	generio	drug's	ther	apeut	ic eauiv	alen <sup>.</sup>	t.	

- [6.] F. Notwithstanding the provisions of Subsections A and B of this section, the administrator for group health coverage may immediately and without prior notice remove a drug from the formulary if the drug:
- (1) is deemed unsafe by the federal food and drug administration; or
- (2) has been removed from the market for any reason.
- [Đ-] G. The administrator for group health coverage prescription drug benefits shall provide to each affected enrollee the following information in plain language regarding prescription drug benefits:
- (1) notice that the group health plan uses one or more drug formularies;
- (2) an explanation of what the drug formulary is;
- (3) a statement regarding the method the group health plan uses to determine the prescription drugs to be included in or excluded from a drug formulary; and
- (4) a statement of how often the group health plan administrator reviews the contents of each drug formulary.
  - [E.] H. As used in this section:
    - (1) "formulary" means the list of prescription

1		

drugs covered by group health coverage; and

a particular patient are to be prescribed."

(2) "step therapy" means a protocol that establishes the specific sequence in which prescription drugs for a specified medical condition and medically appropriate for

SECTION 2. Section 59A-22-49.4 NMSA 1978 (being Laws 2013, Chapter 138, Section 2) is amended to read:

"59A-22-49.4. PRESCRIPTION DRUGS--PROHIBITED FORMULARY CHANGES--NOTICE REQUIREMENTS.--

A. [As of January 1, 2014] An individual or group health insurance policy, health care plan or certificate of health insurance that is delivered, issued for delivery or renewed in this state and that provides prescription drug benefits categorized or tiered for purposes of cost-sharing through deductibles or coinsurance obligations shall [not] only make any of the following changes to coverage for a prescription drug [within one hundred twenty days of any previous change to coverage for that prescription drug, unless a generic version of the prescription drug is available] at the time that the health insurance policy, health care plan or certificate of health insurance is renewed:

- (1) reclassify a drug to a higher tier of the formulary;
- (2) reclassify a drug from a preferred classification to a non-preferred classification, unless that .206394.2

2	the formulary;
3	(3) ir
4	deductible or coinsuran
5	(4) re
6	(5) es
7	requirement;
8	(6) im
9	or
10	(7) im
11	B. Nothing
12	prohibit an insurer fro
13	otherwise, to a formula
14	[ <del>B.</del> ] <u>C.</u> The
15	insured at least sixty
16	impending change when i
17	following modifications
18	<del>(1) re</del>
19	tier of the formulary;
20	<del>(2) re</del>
21	<del>preferred classificatio</del>
22	unless that reclassific
23	<del>lower tier of the formu</del>
24	<del>(3) ar</del>
25	<del>copayment, deductible o</del>
	206394-2

ceclassification	results	in	the	drug	moving	to	а	lower	tier	of
the formulary;										

- (3) increase the cost-sharing, copayment, luctible or coinsurance charges for a drug;
  - (4) remove a drug from the formulary;
- (5) establish a prior authorization equirement:
  - (6) impose or modify a drug's quantity limit;
    - (7) impose a step-therapy restriction.
- B. Nothing in this section shall be construed to prohibit an insurer from adding a new drug, generic or otherwise, to a formulary during a plan year.
- [B.] C. The insurer shall [give the affected insured at least sixty days' advance written notice of the impending change when it is determined that one of the following modifications will be made to a formulary:
- (1) reclassification of a drug to a higher
- (2) reclassification of a drug from a preferred classification, unless that reclassification results in the drug moving to a lower tier of the formulary;
- (3) an increase in the cost-sharing, copayment, deductible or coinsurance charges for a drug; .206394.2

1	(4) removal of a drug from the formulary;
2	(5) addition of a prior authorization
3	requirement;
4	(6) imposition or modification of a drug's
5	quantity limit; or
6	(7) imposition of a step-therapy restriction
7	for a drug] make available to insureds the formulary for a
8	given policy, plan or certificate year no later than sixty days
9	prior to the enrollment deadline for the policy, plan or
10	certificate year.
11	D. An insurer shall establish the following
12	provisions relating to any new drug at the time that the drug
13	is added to a formulary and shall not modify any of the
14	following until the renewal date for the following policy, plan
15	or certificate year:
16	(1) drug tier classification;
17	(2) classification as preferred or non-
18	<pre>preferred;</pre>
19	(3) copayment, deductible or coinsurance
20	requirements for a drug;
21	(4) prior authorization requirements;
22	(5) drug quantity limit; or
23	(6) any step-therapy restriction.
24	E. When an insurer adds a generic drug to a
25	formulary at any time other than at the time of policy, plan or
	.206394.2

13
14
15
16
17
18
19
20
21
22
23
24

25

1

2

3

4

5

6

7

8

9

10

11

12

certificate renewal, the insurer may adjust the cost-sharing,
copayment, deductible or coinsurance requirements, in
accordance with the existing schedule of benefits, applicable
to the drug's therapeutic equivalent that was already in the
drug formulary for that policy, plan or certificate year;
provided that the drug is equivalent in dosage form, safety,
strength, chemical composition, route of administration,
quality, performance characteristics and side effects. The
insurer shall not make any change to the cost-sharing,
copayment, deductible or coinsurance requirements applicable to
the generic drug's equivalent more than once during any policy,
plan or certificate year. An insurer shall give insureds at
least sixty days' advance written notice before making any
changes to cost-sharing, copayment, deductible or coinsurance
requirements applicable to the generic drug's therapeutic
equivalent.

- [C.] F. Notwithstanding the provisions of Subsections A and B of this section, the insurer may immediately and without prior notice remove a drug from the formulary if the drug:
- is deemed unsafe by the federal food and drug administration; or
- has been removed from the market for any (2) reason.
- $[\frac{D_{\bullet}}{G_{\bullet}}]$  The insurer shall provide to each affected .206394.2

24

25

3
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

1

2

insured	the	${\tt following}$	information	in	plain	language	regarding
prescri	otion	n drug bene	efits:				

- (1) notice that the insurer uses one or more drug formularies;
- (2) an explanation of what the drug formulary is;
- (3) a statement regarding the method the insurer uses to determine the prescription drugs to be included in or excluded from a drug formulary; and
- (4) a statement of how often the insurer reviews the contents of each drug formulary.

### $[E_{\bullet}]$ H. As used in this section:

- (1) "formulary" means the list of prescription drugs covered by a policy, plan or certificate of health insurance; and
- (2) "step therapy" means a protocol that establishes the specific sequence in which prescription drugs for a specified medical condition and medically appropriate for a particular patient are to be prescribed."
- SECTION 3. Section 59A-23-7.13 NMSA 1978 (being Laws 2013, Chapter 138, Section 3) is amended to read:
- "59A-23-7.13. PRESCRIPTION DRUGS--PROHIBITED FORMULARY CHANGES--NOTICE REQUIREMENTS.--
- A. [As of January 1, 2014] An individual or group health insurance policy, health care plan or certificate of .206394.2

22

23

24

25

1	health insurance that is
2	renewed in this state an
3	benefits categorized or
4	through deductibles or c
5	make any of the followin
6	prescription drug [ <del>withi</del>
7	<del>previous change to cover</del>
8	a generic version of the
9	time of the health insur
10	certificate of health in
11	(1) red
12	formulary;
13	(2) red
14	classification to a non-
15	reclassification results
16	the formulary;
17	(3) inc
18	deductible or coinsuranc
19	(4) rem
20	(5) est

renewed in this state and that provides prescription drug benefits categorized or tiered for purposes of cost-sharing through deductibles or coinsurance obligations shall [not] only make any of the following changes to coverage for a prescription drug [within one hundred twenty days of any previous change to coverage for that prescription drug, unless a generic version of the prescription drug is available] at the time of the health insurance policy's, health care plan's or certificate of health insurance's renewal:

- (1) reclassify a drug to a higher tier of the formulary;
- (2) reclassify a drug from a preferred classification to a non-preferred classification, unless that reclassification results in the drug moving to a lower tier of the formulary;
- (3) increase the cost-sharing, copayment, leductible or coinsurance charges for a drug;
  - (4) remove a drug from the formulary;
- (5) establish a prior authorization requirement;
  - (6) impose or modify a drug's quantity limit;
  - (7) impose a step-therapy restriction.

    B. Nothing in this section shall be construed to

.206394.2

or

1	prohibit an insurer from adding a new drug, generic or
2	otherwise, to a formulary during a policy, plan or certificate
3	<u>year.</u>
4	[B.] C. The insurer shall [give the affected
5	insured at least sixty days' advance written notice of the
6	impending change when it is determined that one of the
7	following modifications will be made to a formulary:
8	(1) reclassification of a drug to a higher
9	tier of the formulary;
10	(2) reclassification of a drug from a
11	preferred classification to a non-preferred classification,
12	unless that reclassification results in the drug moving to a
13	<del>lower tier of the formulary;</del>
14	(3) an increase in the cost-sharing,
15	copayment, deductible or coinsurance charges for a drug;
16	(4) removal of a drug from the formulary;
17	(5) addition of a prior authorization
18	requirement;
19	(6) imposition or modification of a drug's
20	quantity limit; or
21	(7) imposition of a step-therapy restriction
22	for a drug] make available to insureds the formulary for a
23	given policy, plan or certificate year no later than sixty days
24	prior to the enrollment deadline for the policy, plan or

.206394.2

certificate year.

D. An insurer shall establish the following
provisions relating to any new drug at the time that the drug
is added to a formulary and shall not modify any of the
following until the renewal date for the following policy, plan
or certificate year:

- (1) drug tier classification;
- (2) classification as preferred or non-

preferred;

- (3) copayment, deductible or coinsurance requirements for a drug;
  - (4) prior authorization requirements;
  - (5) drug quantity limit; or
  - (6) any step-therapy restriction.

E. When an insurer adds a generic drug to a formulary at any time other than at the time of policy, plan or certificate renewal, the insurer may adjust the cost-sharing, copayment, deductible or coinsurance requirements, in accordance with the existing schedule of benefits, applicable to the drug's therapeutic equivalent that was already in the drug formulary for that policy, plan or certificate year; provided that the drug is equivalent in dosage form, safety, strength, chemical composition, route of administration, quality, performance characteristics and side effects. The insurer shall not make any change to the cost-sharing, copayment, deductible or coinsurance requirements applicable to

20

21

22

23

24

25

1	the generic drug's equivalent more than once during any policy,
2	plan or certificate year. An insurer shall give insureds at
3	least sixty days' advance written notice before making any
4	changes to cost-sharing, copayment, deductible or coinsurance
5	requirements applicable to the generic drug's therapeutic
6	equivalent.
7	$[\frac{G_{\bullet}}{F_{\bullet}}]$ Notwithstanding the provisions of
8	Subsections A and B of this section, the insurer may
9	immediately and without prior notice remove a drug from the
10	formulary if the drug:
11	(1) is deemed unsafe by the federal food and
12	drug administration; or
13	(2) has been removed from the market for any
14	reason.
15	$[rac{D_{ullet}}{C}]$ The insurer shall provide to each affected
16	insured the following information in plain language regarding
17	prescription drug benefits:
18	(1) notice that the insurer uses one or more

(1) notice that the insurer uses one or more drug formularies;

(2) an explanation of what the drug formulary is;

- (3) a statement regarding the method the insurer uses to determine the prescription drugs to be included in or excluded from a drug formulary; and
  - (4) a statement of how often the insurer

reviews the contents of each drug formulary.

#### [E.] H. As used in this section:

- (1) "formulary" means the list of prescription drugs covered by a policy, plan or certificate of health insurance; and
- (2) "step therapy" means a protocol that establishes the specific sequence in which prescription drugs for a specified medical condition and medically appropriate for a particular patient are to be prescribed."

SECTION 4. Section 59A-46-50.4 NMSA 1978 (being Laws 2013, Chapter 138, Section 4) is amended to read:

"59A-46-50.4. PRESCRIPTION DRUGS--PROHIBITED FORMULARY CHANGES--NOTICE REQUIREMENTS.--

A. [As of January 1, 2014] An individual or group health maintenance organization contract that is delivered, issued for delivery or renewed in this state and that provides prescription drug benefits categorized or tiered for purposes of cost-sharing through deductibles or coinsurance obligations shall [not] only make any of the following changes to coverage for a prescription drug [within one hundred twenty days of any previous change to coverage for that prescription drug, unless a generic version of the prescription drug is available] at the time of health maintenance organization contract renewal:

(1) reclassify a drug to a higher tier of the formulary;

2

3

4

5

6

7

8

9

or

9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

(2) reclassify a drug from a preferred
classification to a non-preferred classification, unless that
reclassification results in the drug moving to a lower tier of
the formulary;
(3) increase the cost-sharing, copayment,
deductible or coinsurance charges for a drug;

- (4) remove a drug from the formulary;
- establish a prior authorization (5) requirement;
  - impose or modify a drug's quantity limit; (6)
    - (7) impose a step-therapy restriction.
- B. Nothing in this section shall be construed to prohibit a health maintenance organization from adding a new drug, generic or otherwise, to a health maintenance organization contract formulary during a contract year.
- [B.] C. The health maintenance organization shall [give the affected subscriber at least sixty days' advance written notice of the impending change when it is determined that one of the following modifications will be made to a formulary:
- (1) reclassification of a drug to a higher tier of the formulary;
- (2) reclassification of a drug from a preferred classification to a non-preferred classification, .206394.2

1	unless that reclassification results in the drug moving to a
2	lower tier of the formulary;
3	(3) an increase in the cost-sharing,
4	copayment, deductible or coinsurance charges for a drug;
5	(4) removal of a drug from the formulary;
6	(5) addition of a prior authorization
7	requirement;
8	(6) imposition or modification of a drug's
9	quantity limit; or
10	(7) imposition of a step-therapy restriction
11	for a drug] make available to enrollees the formulary for a
12	given contract year no later than sixty days prior to the
13	enrollment deadline for the contract year.
14	D. A health maintenance organization shall
15	establish the following provisions relating to any new drug at
16	the time that the drug is added to a formulary and shall not
17	modify any of the following until the renewal date for the
18	following contract year:
19	(1) drug tier classification;
20	(2) classification as preferred or non-
21	<pre>preferred;</pre>
22	(3) copayment, deductible or coinsurance
23	requirements for a drug;
24	(4) prior authorization requirements;
25	(5) drug quantity limit; or
	.206394.2

19

20

21

22

23

24

25

1

2

3

4

### (6) any step-therapy restriction.

5 m
6 c
7 a
8 t
9 d
10 i
11 c
12 c
13 o
14 c
15 t
16 c
17 e
17 e

E. When a health maintenance organization adds a generic drug to a formulary at any time other than at the time of health maintenance organization contract renewal, the health maintenance organization may adjust the cost-sharing, copayment, deductible or coinsurance requirements, in accordance with the existing schedule of benefits, applicable to the drug's therapeutic equivalent that was already in the drug formulary for that contract year; provided that the drug is equivalent in dosage form, safety, strength, chemical composition, route of administration, quality, performance characteristics and side effects. The health maintenance organization shall not make any change to the cost-sharing, copayment, deductible or coinsurance requirements applicable to the generic drug's equivalent more than once during any contract year. A health maintenance organization shall give enrollees at least sixty days' advance written notice before making any changes to cost-sharing, copayment, deductible or coinsurance requirements applicable to the generic drug's therapeutic equivalent.

- [G.] F. Notwithstanding the provisions of Subsections A and B of this section, [the]  $\underline{a}$  health maintenance organization may immediately and without prior notice remove a drug from the formulary if the drug:
  - (1) is deemed unsafe by the federal food and

2	
3	reason
4	
5	shall p
6	informa
7	benefi
8	
9	organiz
10	
11	is;
12	
13	health
14	prescri
15	formula
16	
17	mainte
18	formula
19	
20	
21	drugs o
22	contrac
23	
24	establ:
25	for a s
	.206394

drug	administration	; or
------	----------------	------

- (2) has been removed from the market for any reason.
- $[rac{D.\ The}{G.\ A}]$  health maintenance organization shall provide to each affected subscriber the following information in plain language regarding prescription drug benefits:
- (1) notice that the health maintenance organization uses one or more drug formularies;
- (2) an explanation of what the drug formulary s:
- (3) a statement regarding the method the nealth maintenance organization uses to determine the prescription drugs to be included in or excluded from a drug formulary; and
- (4) a statement of how often the health naintenance organization reviews the contents of each drug formulary.

#### [E.] H. As used in this section:

- (1) "formulary" means the list of prescription drugs covered pursuant to a health maintenance organization contract; and
- (2) "step therapy" means a protocol that establishes the specific sequence in which prescription drugs for a specified medical condition and medically appropriate for 206394.2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1	а	particular	patient	are	to	be	prescribed.
---	---	------------	---------	-----	----	----	-------------

SECTION 5. Section 59A-47-45.4 NMSA 1978 (being Laws 2013, Chapter 138, Section 5) is amended to read:

"59A-47-45.4. PRESCRIPTION DRUGS--PROHIBITED FORMULARY CHANGES--NOTICE REQUIREMENTS.--

A. [As of January 1, 2014] An individual or group health care plan that is delivered, issued for delivery or renewed in this state and that provides prescription drug benefits categorized or tiered for purposes of cost-sharing through deductibles or coinsurance obligations shall [not] only make any of the following changes to coverage for a prescription drug [within one hundred twenty days of any previous change to coverage for that prescription drug, unless a generic version of the prescription drug is available] at the time of health care plan renewal:

- (1) reclassify a drug to a higher tier of the formulary;
- (2) reclassify a drug from a preferred classification to a non-preferred classification, unless that reclassification results in the drug moving to a lower tier of the formulary;
- (3) increase the cost-sharing, copayment, deductible or coinsurance charges for a drug;
  - (4) remove a drug from the formulary;
  - (5) establish a prior authorization requirement;

-	(0) impose of modify a drug s quantity finite; of
2	(7) impose a step-therapy restriction.
3	B. Nothing in this section shall be construed to
4	prohibit a health care plan from adding a new drug, generic or
5	otherwise, to a health care plan formulary during a plan year.
6	[B.] C. The health care plan shall $[give the]$
7	affected subscriber at least sixty days' advance written notice
8	of the impending change when it is determined that one of the
9	following modifications will be made to a formulary:
10	(1) reclassification of a drug to a higher tier
11	of the formulary;
12	(2) reclassification of a drug from a preferred
13	classification to a non-preferred classification, unless that
14	reclassification results in the drug moving to a lower tier of
15	the formulary;
16	(3) an increase in the cost-sharing, copayment,
17	deductible or coinsurance charges for a drug;
18	(4) removal of a drug from the formulary;
19	(5) addition of a prior authorization
20	requirement;
21	(6) imposition or modification of a drug's
22	quantity limit; or
23	(7) imposition of a step-therapy restriction for
24	a drug] make available to subscribers the formulary for a given
25	policy, plan or certificate year no later than sixty days prior

2
3
4
5
6
7
8
9
10
11
12
13
14
15

17

18

19

20

21

22

23

24

25

1	to the enrollment deadline for the plan year.				
2	D. A health care plan shall establish the following				
3	provisions relating to any new drug at the time that the drug				
4	is added to a formulary and shall not modify any of the				
5	following until the renewal date for the following plan year:				
6	(1) drug tier classification;				
7	(2) classification as preferred or non-				
8	preferred;				
9	(3) copayment, deductible or coinsurance				

- (3) copayment, deductible or coinsurance requirements for a drug;
  - (4) prior authorization requirements;
  - (5) drug quantity limit; or
  - (6) any step-therapy restriction.

E. When a health care plan adds a generic drug to a formulary at any time other than at the time of health care plan renewal, the health care plan may adjust the cost-sharing, copayment, deductible or coinsurance requirements, in accordance with the existing schedule of benefits, applicable to the drug's therapeutic equivalent that was already in the drug formulary for that plan year; provided that the drug is equivalent in dosage form, safety, strength, chemical composition, route of administration, quality, performance characteristics and side effects. The health care plan shall not make any change to the cost-sharing, copayment, deductible or coinsurance requirements applicable to the generic drug's

1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	

19

20

21

22

23

24

25

equivalent more than once during any health care plan year. A
health care plan shall give subscribers at least sixty days'
advance written notice before making any changes to
cost-sharing, copayment, deductible or coinsurance requirements
applicable to the generic drug's therapeutic equivalent.
$[rac{G_{ullet}}{F_{ullet}}]$ Notwithstanding the provisions of
Subsections A and B of this section, the health care plan may

- Subsections A and B of this section, the health care plan may immediately and without prior notice remove a drug from the formulary if the drug:
- (1) is deemed unsafe by the federal food and drug administration; or
- (2) has been removed from the market for any reason.
- [Đ.] G. The health care plan shall provide to each affected subscriber the following information in plain language regarding prescription drug benefits:
- (1) notice that the health care plan uses one or more drug formularies;
- (2) an explanation of what the drug formulary is;
- (3) a statement regarding the method the health care plan uses to determine the prescription drugs to be included in or excluded from a drug formulary; and
- (4) a statement of how often the health care plan reviews the contents of each drug formulary.

3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

2

[ <del>E.</del> ]	Η.	As	used	in	this	sections
-------------------	----	----	------	----	------	----------

- (1) "formulary" means the list of prescription drugs covered by a health care plan; and
- (2) "step therapy" means a protocol that establishes the specific sequence in which prescription drugs for a specified medical condition and medically appropriate for a particular patient are to be prescribed."

- 24 -